On May 13, 2025, Core Laboratories (CLB, Financial) received an updated stock assessment from Citigroup analyst Scott Gruber. The analyst maintained a 'Neutral' rating for the stock but adjusted the price target.
Scott Gruber lowered the price target for Core Laboratories (CLB, Financial) from USD 16.00 to USD 13.00. This adjustment marks an 18.75% decrease from the previous price target set by Citigroup.
The adjustment in the price target comes as part of a regular evaluation process, as Core Laboratories (CLB, Financial) continues to navigate the current market conditions. The consistent 'Neutral' rating reflects the analyst's ongoing outlook for the stock.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 5 analysts, the average target price for Core Laboratories Inc (CLB, Financial) is $15.40 with a high estimate of $19.00 and a low estimate of $11.00. The average target implies an upside of 23.40% from the current price of $12.48. More detailed estimate data can be found on the Core Laboratories Inc (CLB) Forecast page.
Based on the consensus recommendation from 5 brokerage firms, Core Laboratories Inc's (CLB, Financial) average brokerage recommendation is currently 3.0, indicating "Hold" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for Core Laboratories Inc (CLB, Financial) in one year is $20.38, suggesting a upside of 63.3% from the current price of $12.48. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the Core Laboratories Inc (CLB) Summary page.
